Raymond Debbane
@Siren, L.l.c.
Latest period2024 - Q3ReportedManaged Assets$2BTotal holdings110
Assets growth rate0%Assets growth rate (2-Q avg)0%Continuous growth in asset value0 quarters
Portfolio positions
This chart displays the top 10 holdings in Siren, L.l.c.'s 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 110 positions.
Assets under management
The assets under management (AUM) of Siren, L.l.c. over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 2B in assets, with a quarterly growth rate of 0% and a 2-quarter average growth rate of 0%. The portfolio is managed by Raymond Debbane, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
KYMRKymera Therapeutics Inc
| 7.03% | $140.557M 2.97M shares@ $47.34 avg price | New Position |
BGNEBeigene Ltd
| 6.33% | $126.47M 563,314 shares@ $224.51 avg price | New Position |
SRRKScholar Rock Holding Corp
| 4.51% | $90.188M 11.259M shares@ $8.01 avg price | New Position |
BCAXBicara Therapeutics Inc
| 3.92% | $78.265M 3.073M shares@ $25.48 avg price | New Position |
ARGXArgenx Se
| 3.9% | $77.868M 143,647 shares@ $542.09 avg price | New Position |
CRNXCrinetics Pharmaceuticals Inc
| 3.35% | $66.923M 1.31M shares@ $51.1 avg price | New Position |
RNAAvidity Biosciences Inc
| 3.31% | $66.173M 1.441M shares@ $45.93 avg price | New Position |
APLSApellis Pharmaceuticals Inc
| 3.13% | $62.503M 2.167M shares@ $28.84 avg price | New Position |
LXRXLexicon Pharmaceuticals Inc
| 3.06% | $61.103M 38.919M shares@ $1.58 avg price | New Position |
IGMSIgm Biosciences Inc
| 2.76% | $55.085M 3.33M shares@ $16.55 avg price | New Position |